|
Objective To investigate the relationship between monocyte chemoattractant protein-1(MCP-1) and macroangiopathy in type 2 diabetics, we compared the serum MCP-1 levels and expression of MCP-1 on monocyte membrane of diabetics with or without macroangiopathy.Methods Total 20 normal controls(group A, 45%women, mean age, 54.30±7.39years) and 30 diabetic patients without macroangiopathy (group B, 43%women, mean age, 54.53±9.19years, course, 4.50±3.50years) and 22 diabetic patients with(group C, 45%women, mean age, 56.45±7.30years, course, 6.21±3.88years) macroangiopathy were recruited. Expression of MCP-1 on monocyte membrane was measured by flow cytometry, serum MCP-1 levels were measured by enzyme linked immunosorbent assay(ELISA).Results 1.Serum MCP-1 levels among groups: Compared with the control group【(39.14±7.43)pg/ml】, the serum MCP-1 levels in diabetics without macroangiopathy【(46.18±5.84)pg/ml】increased significantly (p<0.01), serum MCP-1 levels in diabetics with macroangiopathy【(54.36±9.58)pg/ml】increased further; compared with the diabetics without macroangiopathy group, serum MCP-1 levels in diabetics with macroangiopathy were increased significantly (p<0.01).2.The expression of MCP-1 on monocyte membrane amnong groups: Compared with the control group【(0.28±0.09)%】, the expression of MCP-1 on monocyte membrane in diabetics without macroangiopathy【( 0.70±0.36 ) %】were significantly higher(p<0.01), the expression of MCP-1 on monocyte membrane in diabetics with macroangiopathy【(1.02±0.33)%】increased further; compared with the diabetics without macroangiopathy group, the expression of MCP-1 on monocyte membrane in diabetics with macroangiopathy increased significantly higher(p<0.01).3.Correlation analysis: Linear correlation analysis showed that serum MCP-1 levels had positive relationship with the expression of MCP-1 on monocyte membrane in diabetics(r=0.83, p<0.01); the serum MCP-1 levels had positive relationship with FBG, HbA1c and LgHoma-IR(r=0.5, p<0.01; r=0.29, p<0.05; r=0.61, p<0.01); the expression of MCP-1 on monocyte membrane had positive relationship with FBG, HbA1c and LgHoma-IR(r=0.67, p<0.01; r=0.38, p<0.01; r=0.76, p<0.01).Conclusions Type 2 diabetics in vivo had the enhanced expression of MCP-1, which might take part in the development and progression of macroangiopathy. Objective To observe the effect of short-term insulin intensive treatment on the monocyte chemoattractant protein-1(MCP-1) expression on the monocyte surface and serum MCP-1 levels in newly-diagnosed type 2 diabetic patients, and probe its effect of anti-inflammation.Methods 20 newly-diagnosed type 2 diabetic patients were treated by insulin intensive treatment for 2 weeks, the MCP-1 expression on the monocyte surface(by flow cytometry), serum MCP-1 levels(by enzyme linked immunosorbent assay, ELISA), fasting blood glucose(FBG), postprandial blood glucose(P2hBG), white blood cell count(WBC) and the neutrocyte percents(N%) were measured pre-treatment and post- treatment. The other 20 healthy volunteers (45%women; mean age, 54.30±7.39years) served as control subjects.Results 1.Compared with the control group, MCP-1 expression on monocyte surface and serum MCP-1 levels of patients with type 2 diabetes increased significantly,which were (0.89±0.26)% VS (0.28±0.09%)(p<0.01) and (49.53±3.47pg/ml) VS (39.14±7.43pg/ml)(p<0.01).2.Compared with pre-treatment, after 2 weeks of insulin intensive treatment, 1) FBG and P2hBG were significantly decreased, which were (11.18±1.73)mmol/L VS (6.37±1.07)mmol/L and (17.92±2.08)mmol/L VS (8.27±2.12)mmol/L, p<0.01; 2) WBC and N% after treatment were much lower than those of pre-treatment, which were (7.39±1.56)×109/L VS (5.52±1.12)×109/L and (64.61±5.45)% VS (56.23±4.71)%, p<0.01; 3) The MCP-1 expression on the monocyte surface and serum MCP-1 levels decreased significantly compared with pre-treatment, which were (0.50±0.18)% VS(0.89±0.26)% and (44.53±3.97)pg/ml VS(49.53±3.47)pg/ml, respectively, (p<0.01).3.Correlation analysis: Linear correlation analysis showed that the MCP-1 expression on monocyte surface had significant and positive relationship with serum MCP-1 levels in patients with type2 diabetes(r=0.47, p<0.01); after 2 weeks of insulin treatment, the descent of serum MCP-1 levels had positive relationship with the descent of FBG(r=0.58, p<0.01), had no relationship with the descent of P2hBG(r=0.08,p>0.05) and LgHOMA-IR(r=0.39, p>0.05); after 2 weeks of insulin treatment, the descent of MCP-1 expression on monocyte membrane had no relationship with the descent of FBG(r=0.033, p>0.05), P2hBG(r=0.27, p>0.05) and LgHOMA-IR(r=0.10, p>0.05).Conclusions Short-term insulin intensive therapy has the effect of alleviating inflammation reaction in type 2 diabetics.
|